LifeVantage Expands MB System™ to International Markets
LifeVantage Corporation (Nasdaq: LFVN), a leader in health and wellness products aimed at activating optimal health at the cellular level, has announced the international expansion of its MindBody GLP-1 System™, now branded as the MB System™.
This strategic move follows a remarkable 49% year-over-year increase in U.S. revenue for fiscal Q2 ending December 31, 2024, largely attributed to the system’s domestic success and supporting clinical data.
Launch Details and Availability
The MB System™ became accessible on March 15 to both LifeVantage Consultants and customers in Japan. Simultaneously, it was made available exclusively to Consultants in Australia, New Zealand, Europe, the UK, Mexico, and Thailand, with customer access in these regions commencing on April 25.
Understanding the MB System™
Designed to naturally stimulate the body’s own production of glucagon-like peptide-1 (GLP-1), the MB System™ offers a range of long-term health benefits extending beyond weight management. GLP-1 is a hormone integral to metabolic health, influencing appetite regulation, insulin secretion, and gastrointestinal motility.
Key Benefits of the MB System™:
- Enhanced Metabolic Health – Supports the body’s natural metabolic processes, promoting energy balance and weight management.
- Improved Gut Health – Aids in maintaining a healthy gut microbiome, which is crucial for digestion and overall well-being.
- Hormonal Balance – Assists in regulating hormones related to appetite and glucose metabolism.
MB System™ International Availability
The following table provides an overview of when and where the MB System™ is being launched internationally:
| Country/Region | Consultant Access | Customer Access |
|---|---|---|
| Japan | 15 March 2025 | 15 March 2025 |
| Australia | 15 March 2025 | 25 April 2025 |
| New Zealand | 15 March 2025 | 25 April 2025 |
| Europe & UK | 15 March 2025 | 25 April 2025 |
| Mexico | 15 March 2025 | 25 April 2025 |
| Thailand | 15 March 2025 | 25 April 2025 |
| Philippines | Early Summer 2025 | Early Summer 2025 |
| Taiwan | Early Summer 2025 | Early Summer 2025 |
| Canada | Late 2025 | Late 2025 |
Global Demand for GLP-1 Solutions
The global interest in GLP-1 and metabolic health solutions is on the rise. The GLP-1 pharmaceutical market was valued at $53.46 billion in 2024 and is projected to grow at a CAGR of 17.5%, reaching approximately $156.71 billion by 2030.
Scientific Validation and Research
LifeVantage has completed an international in vitro cell study on the MB System™, demonstrating its efficacy in activating GLP-1 production. The study utilised ELISA (Enzyme-Linked Immunosorbent Assay) to quantify total GLP-1 production and employed fluorescent microscopy for visualisation.
The research focused on the synergistic potential of the system’s active blends, designed to enhance GLP-1 production through:
- Direct activation of L-cells with a proprietary blend of five naturally derived ingredients.
- Optimisation of the gut microbiome using resistant starches.
Future Market Expansions
LifeVantage plans to extend the availability of the MB System™ to additional markets, including the Philippines and Taiwan in early summer, followed by Canada later in the year. This global rollout underscores the company’s commitment to providing natural activation solutions worldwide.
About LifeVantage Corporation
Founded in 2003 and headquartered in Lehi, Utah, LifeVantage is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock genetic potential and promote health.
The company’s product line includes scientifically validated activators such as:
- Protandim® family
- TrueScience® Liquid Collagen
- MB System™
Q&A Section
Q1: What is GLP-1, and why is it important?
A1: GLP-1 (glucagon-like peptide-1) is a hormone that plays a crucial role in regulating appetite, insulin secretion, and gastrointestinal motility. It is essential for maintaining metabolic health and has implications for weight management and glucose regulation.
Q2: How does the MB System™ enhance GLP-1 production?
A2: The MB System™ employs a dual mechanism:
- It directly activates L-cells in the colon using a proprietary blend of five naturally derived ingredients.
- It optimises the gut microbiome environment with resistant starches, thereby enhancing the body’s natural GLP-1 production.
Q3: In which countries is the MB System™ currently available?
A3: As of March 15, 2025, the MB System™ is available to LifeVantage Consultants and customers in Japan. It is also accessible exclusively to Consultants in Australia, New Zealand, Europe, the UK, Mexico, and Thailand, with customer access in these regions starting on April 25, 2025.
Q4: What are LifeVantage’s future plans for the MB System™?
A4: LifeVantage intends to launch the MB System™ in the Philippines and Taiwan in early summer 2025, followed by Canada later in the year, completing the global rollout and reinforcing its commitment to providing natural activation solutions worldwide.
